NewsRoom Articles - Page 35 of 45

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical developmentCybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybinThe high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants were dosed…

TuesdaySep 20, 2022 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organizationQSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populationsCompany creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “The…

MondaySep 19, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each yearThe current standard of care for GBM is ineffective for approximately 60% of patientsInitial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80% CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the H.C. Wainwright…

FridaySep 16, 2022 11:30 am

Trucking Supply Chain Tech Innovator Freight Technologies Inc. (NASDAQ: FRGT) Reports New Revenue Growth on B2B Marketplace Solution

Cross-border shipping solutions developer Freight Technologies Inc. is a B2B marketplace builder focused on providing the commercial trucking industry with transparent and efficient automation to simplify necessary communications, coordination and paperworkFreight Technologies, also known as Fr8Tech, upgraded its brand and ticker symbol earlier this year following its reverse merger with Hudson Capital Inc.Amid the upgrade, the company is reporting new record quarterly revenue that grew by 60 percent over the previous quarter and 45 percent YOYThe company expects improving market conditions as the nation continues to rebound from COVID’s economic effects to drive long-term growth At the height of the…

FridaySep 16, 2022 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), Growing its Market Share, One Patent at a Time

Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the worldIts latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage productsLexaria remains committed to advancing its research and expanding the indications and efficacy of its DehydraTECH technology, as it looks to benefit from the CBD industry, projected to be valued at $111.8 billion by 2030, and the cardiovascular…

WednesdaySep 14, 2022 10:00 am

Freight Technologies Inc. (NASDAQ: FRGT) Marks Milestone Intended to Foster Company Growth

Freight Technologies is an emerging growth company whose unique solutions suite is designed to optimize and automate the supply chain process and provide a platform for B2B cross-border shipping in North AmericaThe company recently filed Form F-1 with the SEC registering more than 19 million ordinary shares for resale by selling shareholders identified in the registration statementCEO Javier Selgas hailed the milestone as a move that positions the company to continue to work with the capital markets to foster company growthThe filing comes amid favorable market reports that evidence resurgence of the truck freight market in North America Emerging growth…

WednesdaySep 14, 2022 9:30 am

Cepton, Inc. (NASDAQ: CPTN) Remains Committed to Delivering Enhanced Safety for All Drivers; Works with Top 10 Global Automotive OEMs to Commercialize Lidar

Evidence suggests that current ADAS solutions relying on cameras for perception are not yet safe enough due to camera’s limited capabilities of providing accurate perception data 24/7In a recent article authored for Forbes, Cepton's co-founder and CEO Jun Pei calls for widespread adoption of sensor suites that include complementary technologies–including lidar, camera, and radar–that seamlessly work together to enhance safety for driversCepton remains committed to deploying lidar in all vehicles with the goal of making the driving experience safer and more efficient for all road participants; expands collaboration with Koito to extend beyond its current OEM series production program "If…

WednesdaySep 14, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Strengthens Board of Directors to Boost Efforts toward Regulatory Approval of Potential Treatment for Hypertension

Lexaria Bioscience is a global innovator in drug delivery platforms whose lead technology, DehydraTECH, has been shown to increase the bioavailability of APIsThe company recently announced that Catherine Turkel, PharmD, Ph.D., has joined its board of directorsDr. Turkel, who brings over 20 years’ experience, has previously formulated Food and Drug Administration (“FDA”) registration and commercial strategic plans, as well as led global development programs for pharmaceutical and biologic treatmentsDr. Turkel will lend her drug registration experience and regulatory expertise to Lexaria at a time when the company is journeying toward regulatory approval for DehydraTECH-CBD, its drug candidate for the treatment…

TuesdaySep 13, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomasGlioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosisCNS’s efforts to fill an unmet medical need arise from promise shown during Berubicin’s initial development by another company over 15 years ago, which included a small-scale human safety trial that produced a patient with no detectable cancer and others that saw tumor shrinkage and stable diseaseThe…

TuesdaySep 13, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC), Cannabis Brand Builder, is Ramping Up its HR Productivity and Effectiveness One Appointment at a Time

A 2017 study by McKinsey & Company showed that high performers tend to be 400% more productive than average ones. This outlook has shaped Flora Growth’s hiring strategy for 2022, with the appointment of several key individuals whose proven talents and productivity are seen as critical to the company’s goal of delivering the most compelling customer experiences, most recently with the appointment of Elshad Garayev as Flora’s Chief Financial Officer (“CFO”)Mr. Garayev’s appointment marks the latest addition to a growing list of leaders ready to elevate the company to another level of international performance In a study conducted in 2017 by…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000